Screener
Charles River Laboratories CRL Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | -6%— | -4.6%— | -3.6%— | —— | —— | |
| Returns | ||||||
| Return on equity | -7.7%— | -6%— | -4.4%— | —— | —— | |
| Return on invested capital | 6.4%+0.9pp | 6%+2.8pp | 5.3%+1.7pp | 5.9%+1.0pp | 5.5%-0.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Liquidity | ||||||
| Current ratio | 1.3×0.0× | 1.4×-0.1× | 1.3×-0.1× | 1.4×-0.1× | 1.4×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 1.1×+0.2× | 1×+0.1× | 0.8×0.0× | 0.8×0.0× | 0.8×+0.1× | |
| Net debt / EBITDA | 4.2×+0.8× | 4.1×+0.6× | 3.4×+0.2× | 3.1×+0.1× | 3.4×+0.4× | |
| Per Share | ||||||
| Book value per share | $59.13-13.0% | $60.07-4.4% | $63.85-4.8% | $68.90-6.0% | $68.00-5.3% | |
| Valuation | ||||||
| Market capitalization | $12.56B+70.1% | $8.49B+10.3% | $9.82B+4.0% | $7.7B-24.3% | $7.29B-31.5% | |
| Price / sales | 3.1×+1.3× | 2.1×+0.2× | 2.4×+0.1× | 1.9×-0.6× | 1.8×-0.8× | |
| Price / book | 4.4×+2.2× | 2.9×+0.5× | 3.1×+0.4× | 2.3×-0.4× | 2.2×-0.7× | |
| EV / EBITDA | 22.9×+10.0× | 16.2×+2.9× | 17.2×+2.3× | 12.9×-1.8× | 12.8×-2.1× |
FAQ
- What are Charles River Laboratories's profit margins?
- Charles River Laboratories (CRL) runs a 84.7% gross margin and a 13.0% operating margin, with a -6.0% net margin.
- Where do Charles River Laboratories's ratios come from?
- Every ratio is computed from Charles River Laboratories's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
